Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

NCT06772220•Oregon Health and Science University

Summary

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Eligibility

Age

40 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
•2. Currently treated with levodopa at a minimum dose of 300 mg/day
•3. Montreal Cognitive Assessment (MOCA) ≥15
•4. Demonstrated capacity to provide informed consent.
•5. 40-90 years of age
•6. Estimated glomerular filtration rate ≥60
•7. Absence of uncontrolled hypertension in medical history
•8. Absence of insulin use

Exclusion Criteria

•\-

Locations (1)

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

Key Dates

Start Date

March 5, 2024

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

January 13, 2025

Enrollment

150

ESTIMATED participants

Conditions

Parkinson&Amp;#39;s Disease

Interventions

Folic Acid 1 MG

DIETARY_SUPPLEMENT

Vitamin B6 25 MG

DIETARY_SUPPLEMENT

Vitamin B12

DIETARY_SUPPLEMENT

Contacts

Madeline Armendariz Sullivan

CONTACT

503-501-8478 PDResearch@ohsu.edu

Neurosurgical Outcome Network

NCT06724029

AneurysmsArteriovenous Malformations+21 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions